CD19/CD22 Dual Targeted (Chimeric Antigen Receptor) CAR-T Therapy for Relapsed or RE Fractory (R/R) B-CELL Non-Hodgkin Lymphoma (B-NHL)

被引：0
|
作者：
Zhao, Houli [1 ,2 ,3 ]
Hu, Yongxian [1 ,2 ,3 ]
Nagler, Arnon [4 ]
Chang, Alex Hongsheng [5 ]
Huang, He [1 ,2 ,3 ]
机构：
[1] Zhejiang Univ, Affiliated Hosp 1, Hangzhou, Zhejiang, Peoples R China
[2] Zhejiang Prov Engn Lab Stem Cell & Immun Therapy, Hangzhou, Zhejiang, Peoples R China
[3] Zhejiang Univ, Hangzhou, Zhejiang, Peoples R China
[4] Chaim Sheba Med Ctr, Tel Hashomer, Israel
[5] Shanghai YaKe Biotechnol Ltd, Shanghai, Shanghai, Peoples R China
来源：
BONE MARROW TRANSPLANTATION | 2020年 / 55卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
O034
引用
收藏
页码：44 / 45
页数：2
相关论文
共 50 条
  • [31] Safety and Efficacy of Humanized Versus Murinized CD19 and CD22 CAR T-Cell Cocktail Therapy for Refractory/Relapsed B-Cell Lymphoma
    Huang, Lefu
    Li, Jingjing
    Yang, Junfang
    Zhang, Xian
    Zhang, Min
    He, Jiujiang
    Zhang, Gailing
    Li, Wenqian
    Wang, Hui
    Li, Jianqiang
    Lu, Peihua
    CELLS, 2022, 11 (24)
  • [32] Response to Bridging Therapy (BT) before CAR-T Cell Infusion Predicts Outcomes for Relapsed/Refractory (R/R) Aggressive B-Cell Non-Hodgkin Lymphoma (NHL)
    Khurana, Arushi
    Al Saleh, Abdullah S.
    Gandhi, Sangeetha
    Truong, Tuan A.
    Bennani, Nabila
    Paludo, Jonas
    Villasboas, Jose C.
    Johnston, Patrick B.
    Ansell, Stephen M.
    Lin, Yi
    BLOOD, 2020, 136
  • [33] Effectiveness and safety of CD22 and CD19 dual-targeting chimeric antigen receptor T-cell therapy in patients with relapsed or refractory B-cell malignancies: A meta-analysis
    Nguyen, Thi Thuy
    Thanh Nhu, Nguyen
    Chen, Chia-Ling
    Lin, Chiou-Feng
    CANCER MEDICINE, 2023, 12 (18): : 18767 - 18785
  • [34] C-CAR039, a Novel Anti-CD20/CD19 Bi-Specific CAR T-Cell Therapy Shows Deep and Durable Clinical Benefits in Patients with Relapsed or Refractory (r/r) B-Cell Non-Hodgkin Lymphoma (B-NHL) in Long Term Follow up
    Li, Ping
    Yu, Wen-Juan
    Zhou, Lili
    Yang, Min
    Ye, Shiguang
    Zhu, Judy
    Huang, Jiaqi
    Zhang, Yan
    Li, Lanfang
    Zhao, Jing
    Zhu, Kevin
    Li, Jing
    Zheng, Chengxiao
    Lan, Liping
    Wan, Hui
    Yao, Yihong
    Zhang, Huilai
    Zhou, Daobin
    Jin, Jie
    Liang, Aibin
    BLOOD, 2023, 142
  • [35] CAR-T Cell Therapy With CRISPR/CAS9 Engineering for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia, With Universal Dual Target CD19/CD22
    Baptista, Gabriel
    Carvalho, Julia
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S529 - S529
  • [36] Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma
    Makita, Shinichi
    Yoshimura, Kiyoshi
    Tobinai, Kensei
    CANCER SCIENCE, 2017, 108 (06) : 1109 - 1118
  • [37] A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia
    Wang, Yiyun
    Yang, Yingying
    Hong, Ruimin
    Zhao, Houli
    Wei, Guoqing
    Wu, Wenjun
    Xu, Huijun
    Cui, Jiazhen
    Zhang, Yanlei
    Chang, Alex H.
    Hu, Yongxian
    Huang, He
    BLOOD CANCER JOURNAL, 2020, 10 (10)
  • [38] CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas
    Cao, Yang
    Xiao, Yi
    Wang, Na
    Wang, Gaoxiang
    Huang, Liang
    Hong, Zhenya
    Meng, Li
    Zhou, Xiaoxi
    Wang, Jue
    Yang, Yang
    Xu, Hao
    Zhang, Shangkun
    Xiao, Min
    Chen, Liting
    Zheng, Miao
    Li, Chunrui
    Mao, Xia
    Gu, Chaojiang
    Zhang, Tongcun
    Zhang, Yicheng
    Zhou, Jianfeng
    TRANSPLANTATION AND CELLULAR THERAPY, 2021, 27 (11): : 910.e1 - 910.e11
  • [39] Prominent efficacy and good safety of sequential CD19 and CD22 CAR-T therapy in relapsed/refractory adult B-cell acute lymphoblastic leukemia
    Tingting Yang
    Yetian Dong
    Mingming Zhang
    Jingjing Feng
    Shan Fu
    Pingnan Xiao
    Ruimin Hong
    Huijun Xu
    Jiazhen Cui
    Simao Huang
    Guoqing Wei
    Delin Kong
    Jia Geng
    Alex H. Chang
    He Huang
    Yongxian Hu
    Experimental Hematology & Oncology, 14 (1)
  • [40] A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia
    Yiyun Wang
    Yingying Yang
    Ruimin Hong
    Houli Zhao
    Guoqing Wei
    Wenjun Wu
    Huijun Xu
    Jiazhen Cui
    Yanlei Zhang
    Alex H. Chang
    Yongxian Hu
    He Huang
    Blood Cancer Journal, 10
12345